Amorphous solid dispersions stabilized by one or more polymer (s) have been widely used
for delivering amorphous drugs with poor water solubilities, and they have gained great …

Functional liquid‐based interfaces, with their inhomogeneous regions that emphasize the
functionalized liquids, have attracted much interest as a versatile platform for a broad …

Polymorphism occurs widely in pharmaceutical solids, and must be thoroughly studied
during product development. Twenty-four years after ritonavir (RTV) Form II materialized, we …

Amorphous drugs are used to improve bioavailability of poorly water-soluble drugs.
Crystallization must be managed to take full advantage of this formulation strategy …

Molecules at a liquid/vapor interface have different organizations and mobilities from those
in the bulk. These differences potentially influence the rate of crystal nucleation, but the …

Amorphous pharmaceutical solids (APS) are single-or multi-component systems in which
drugs exist in high-energy states with long-range disordered molecular packing. APSs have …

Low concentration polymer additives can significantly alter crystal growth kinetics of
molecular liquids and glasses. However, the effect of polymer concentration on nucleation …

A thorough understanding of effects of polymers on crystallization of amorphous drugs is
essential for rational design of robust amorphous solid dispersion (ASD), since …

In this study, the effects of polyethylene glycol (PEG) and polyvinylpyrrolidone (PVP) on the
nucleation and crystal growth kinetics of acephate were systematically investigated. The …

Amorphous solid dispersion (ASD) is a highly effective formulation strategy for enhancing
the water solubility and oral bioavailability of drugs that are poorly soluble in water. Despite …